ClinicalTrials.gg
Active, not recruitingNCT01896479EXAMINERUpdated Oct 20, 2026Results posted

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

A Phase 4 interventional study of Cabozantinib (XL184) 140 mg and Cabozantinib (XL184) 60 mg in Medullary Thyroid Cancer, sponsored by Exelixis. Active, not recruiting at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Exelixis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Carcinoma, Medullary with a site in France — none open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Medullary · France.

Enrollment
6th of 13
247 · median 117
Started
2015
the only one that year
Phase 4
Only one
of the 17
Registered
6th of 17
by date
Lead sponsor
2 of 17
Exelixis

Among the 17 studies in Carcinoma, Medullary with a site in France, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 4, and was the 6th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

None of the 17 studies in Carcinoma, Medullary with a site in France is open now. The open studies under Carcinoma, Medullary, anywhere →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Carcinoma, Medullary with a site in France as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

03

Conditions studied

  • Medullary Thyroid Cancer

Keywords

  • thyroid cancer
  • medullary thyroid cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has a confirmed diagnosis of MTC.
  2. All subjects will need to be tested for RET mutational status. If subjects do not have documentation confirming they have a RET mutation, a sample of their tumor (taken either during screening or from a procedure within 6 months prior to randomization) will need to be tested.
  3. The subject has per 1.1 that is as determined by the investigator based upon computerized tomography (CT), magnetic resonance imaging (MRI), PET scan, bone scan, or X-ray taken within 28 days before randomization.
  4. The subject has documented worsening of disease (progressive disease) at screening as compared with a previous CT, PETor MRI scan, bone scan, or X-ray as determined by the investigator per RECIST 1.1 on qualifying screening images taken within 28 days prior to randomization as compared to previous images taken within 14 months before the qualifying screening images.
  5. The subject has recovered to baseline or v4.0 (Common Terminology Criteria for Adverse Events, version 4.0) ≤ Grade 1 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy.
  6. The subject has an (ECOG) performance status of ≤ 1 at screening.
  7. The subject has adequate organ and marrow function
  8. The subject is capable of understanding and complying with the protocol requirements and has signed the document.
  9. Sexually active fertile subjects and their partners must agree to use medically accepted methods of (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. The subject has previously received cabozantinib.
  2. Receipt of any type of small molecule kinase inhibitor or hormonal therapy within 28 days or 5 half-lives of the compound or active metabolites, whichever is shorter, before randomization.
  3. Receipt of any systemic anti-tumor therapy within 28 days of randomization (42 days for nitrosoureas or/ mitomycin C).
  4. Receipt of any other type of agent within 28 days of randomization.
  5. Receipt of radiation therapy within 28 days (14 days for radiation for bone ) of randomization or radionuclide treatment within 42 days of randomization. Subject is ineligible if there are any ongoing complications from prior radiation therapy.
  6. The subject has untreated and/or active (progressing or requiring anticonvulsants or for symptomatic control) central nervous system (CNS) metastasis. Must have completed radiation therapy ≥ 28 days prior to randomization and be stable without corticosteroids or anti-convulsant treatment for ≥ 10 days.
  7. Treatment at therapeutic doses with oral anticoagulants or inhibitors (examples are warfarin and clopidogrel).
  8. The subject has uncontrolled, significant intercurrent illness including, but not limited to, cardiovascular disorders, gastrointestinal disorders, active infections, non-healing wounds, recent surgery.
  9. interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization.
  10. The subject is unable to swallow multiple tablets or capsules.
  11. The subject has a previously identified allergy or to components of the study treatment formulation.
  12. The subject is pregnant or breastfeeding.
  13. The subject has had a diagnosis of another within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Cabozantinib (XL184) 60 mg

    Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.

    Drug: Cabozantinib (XL184) 60 mg · Drug: Placebo capsule

  • Experimental
    Cabozantinib (XL184) 140 mg

    Cabozantinib (XL184) 140 mg as tablets and placebo capsules administered orally once a day.

    Drug: Cabozantinib (XL184) 140 mg · Drug: Placebo tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS per BIRC per RECIST 1.1 was measured from randomization until the date of first documented disease progression or date of death from any cause, whichever came first, and was assessed for up to 31 months. The prespecified primary analysis was triggered by the required number of at least 150 events occurring in the ITT population, The data cutoff date for this event-driven analysis in the ITT population was when a total of 155 events were reported. Median PFS was calculated using the Kaplan-Meier estimates.

    Time frame: Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per BIRC Per RECIST 1.1

    ORR per BIRC per RECIST 1.1 is the percentage of ITT participants who experienced a best overall response of complete response (CR) or partial response (PR), confirmed ≥ 28 days later, CR defined as disappearance of all non-target lesions. All lymph nodes must have been non-pathological in size (\<10 mm short axis). PR defined as unequivocal progression of non-target lesions. Unequivocal progression was to trump target lesion status. It must have been representative of overall disease status change, not a single lesion increase.

    Time frame: Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months

07

Results

Posted Sep 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneCabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mg
Started123124
Received at least 1 dose of study drug123124
Completed123124
Not completed00

Outcome measures

PrimaryProgression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS per BIRC per RECIST 1.1 was measured from randomization until the date of first documented disease progression or date of death from any cause, whichever came first, and was assessed for up to 31 months. The prespecified primary analysis was triggered by the required number of at least 150 events occurring in the ITT population, The data cutoff date for this event-driven analysis in the ITT population was when a total of 155 events were reported. Median PFS was calculated using the Kaplan-Meier estimates.

Time frame:
Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months
Reported as:
Median · months
Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
monthsCabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mg
Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)11 (8.3 to 13.6)13.9 (9.0 to 16.6)
Statistical analysis
  • Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg · Log Rank · p = 0.1916 (Stratification factors comprised RET M918T mutational status (positive, negative, and unknown).) · Cox proportional hazard: 1.24 · 95% CI 0.90 to 1.70
SecondaryObjective Response Rate (ORR) Per BIRC Per RECIST 1.1

ORR per BIRC per RECIST 1.1 is the percentage of ITT participants who experienced a best overall response of complete response (CR) or partial response (PR), confirmed ≥ 28 days later, CR defined as disappearance of all non-target lesions. All lymph nodes must have been non-pathological in size (\<10 mm short axis). PR defined as unequivocal progression of non-target lesions. Unequivocal progression was to trump target lesion status. It must have been representative of overall disease status change, not a single lesion increase.

Time frame:
Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per BIRC Per RECIST 1.1
percentage of participantsCabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mg
Objective Response Rate (ORR) Per BIRC Per RECIST 1.133 (25.09 to 42.40)33 (24.88 to 42.08)
Statistical analysis
  • Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg · Cochran-Mantel-Haenszel · p = 0.9437 · Odds ratio (or): 1.0195 · 95% CI 0.6 to 1.7Stratification factors comprised RET M918T mutational status (positive, negative, and unknown).

Adverse events

Collected over From first dose to 30 days following last dose (up to a maximum of 61 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib (XL184) 60 mg59/123 (48%)55/123 (44.7%)122/123 (99.2%)
Cabozantinib (XL184) 140 mg51/124 (41.1%)62/124 (50%)123/124 (99.2%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventCabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mg
Medullary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/1239/124
PneumoniaInfections and infestations5/1235/124
AnaemiaBlood and lymphatic system disorders3/1231/124
AstheniaGeneral disorders3/1231/124
SepsisInfections and infestations3/1232/124
NauseaGastrointestinal disorders0/1233/124
HypercalcaemiaMetabolism and nutrition disorders2/1233/124
HypocalcaemiaMetabolism and nutrition disorders2/1233/124
DiarrhoeaGastrointestinal disorders2/1232/124
DeathGeneral disorders2/1230/124
Most frequent other events
Showing 10 of 74
Most frequent other events
EventCabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mg
DiarrhoeaGastrointestinal disorders83/12389/124
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders67/12366/124
Weight decreasedInvestigations38/12365/124
FatigueGeneral disorders43/12348/124
Decreased appetiteMetabolism and nutrition disorders44/12346/124
HypertensionVascular disorders25/12342/124
NauseaGastrointestinal disorders24/12340/124
Mucosal inflammationGeneral disorders23/12338/124
Aspartate aminotransferase increasedInvestigations35/12338/124
Alanine aminotransferase increasedInvestigations36/12336/124

Baseline characteristics

Measured in the Safety Population, which included participants who received any amount of study drug.

Age, Categorical
Age, Categorical(Participants)Cabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mgTotal
<=18 years000
Between 18 and 65 years8578163
>=65 years384684
Sex: Female, Male
Sex: Female, Male(Participants)Cabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mgTotal
Female335083
Male9074164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mgTotal
Hispanic or Latino268
Not Hispanic or Latino103102205
Unknown or Not Reported181634
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mgTotal
American Indian or Alaska Native000
Asian11819
Native Hawaiian or Other Pacific Islander000
Black or African American000
White92102194
More than one race213
Unknown or Not Reported181331
Region of Enrollment
Region of Enrollment(participants)Cabozantinib (XL184) 60 mgCabozantinib (XL184) 140 mgTotal
Romania9918
Hungary415
Russia141630
Spain61218
Canada213
Netherlands448
South Korea10717
Sweden516
Poland131730
Italy91322
Israel358
Australia192039
France211334
Croatia459
08

Study locations

49 sites
  • St Leonards, New South Wales 2065, Australia
  • Herston, Queensland 4006, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Parkville, Victoria 3050, Australia
  • Québec, Quebec JIH 5N4, Canada
  • Toronto, M5G 2M9, Canada
  • Osijek, 31000, Croatia
  • Zagreb, 10000, Croatia
  • Zagreb, 1000, Croatia
  • Bordeaux, Gironde 33076, France
  • Angers, Maine-et-Loire 49933, France
  • Lyon, Rhône 69373, France
  • Villejuif, Val-de-Marne 94805, France
  • Dijon, 21079, France
  • Paris, 75013, France
  • Strasbourg, 67065, France
  • Budapest, 1088, Hungary
  • Debrecen, 4032, Hungary
  • Jerusalem, 91120, Israel
  • Petah Tikva, 49100, Israel
  • Safed, 13100, Israel
  • Catania, CT 95124, Italy
  • Roma, RM 00161, Italy
  • Siena, SI 53100, Italy
  • Pisa, Tuscany 56124, Italy
  • Milan, 20133, Italy
  • Padua, 35138, Italy
  • Torino, 10153, Italy
  • Amsterdam, North Holland 1066 CX, Netherlands
  • Leiden, South Holland 2333 ZA, Netherlands
  • Groningen, 9713 GZ, Netherlands
  • Poznan, Greater Poland Voivodeship 60-355, Poland
  • Gliwice, Silesian Voivodeship 44-100, Poland
  • Bucharest, 10825, Romania
  • Bucharest, 11863, Romania
  • Cluj-Napoca, 400058, Romania
  • Timișoara, 300723, Romania
  • Novosibirsk, 630068, Russia
  • Obninsk, 249036, Russia
  • Saint Petersburg, 197089, Russia
  • Yaroslavl, 150040, Russia
  • Goyang, Gyeonggido 410769, South Korea
  • Seoul, 110744, South Korea
  • Seoul, 135-710, South Korea
  • Barcelona, 08035, Spain
  • Madrid, 28034, Spain
  • Madrid, 28046, Spain
  • Lund, Skane Ian SE-22185, Sweden
  • Uppsala, Uppsala Ian 75185, Sweden
09

References and documents

Publications

  • Capdevila J, Klochikhin A, Leboulleux S, Isaev P, Badiu C, Robinson B, Hughes BGM, Keam B, Parnis F, Elisei R, Gajate P, Gan HK, Kapiteijn E, Locati L, Mangeshkar M, Faoro L, Krajewska J, Jarzab B. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid. 2022 May;32(5):515-524. doi: 10.1089/thy.2022.0027. PubMed 35403447 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Jul 2020, 64 months.

Results were first posted in Sep 2025, 5 years 1 month after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2013
First posted
Jul 11, 2013
StartActual
Feb 25, 2015
Primary completionActual
Jul 15, 2020
CompletionEst.
Jan 31, 2035
Results delay requested
Jul 13, 2021
Results first posted
Sep 2, 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and site details
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01896479
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Feb 25, 2015
Primary completion
Jul 15, 2020
Completion
Jan 31, 2035 (estimated)
Results posted
Sep 2, 2025
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion